Cargando…

Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome

Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Erturk, Biray, Karaca, Emin, Aykut, Ayca, Durmaz, Burak, Guler, Ahmet, Buke, Baris, Yeniel, Ahmet Ozgur, Ergenoglu, Ahmet Mete, Ozkinay, Ferda, Ozeren, Mehmet, Kazandi, Mert, Akercan, Fuat, Sagol, Sermet, Gunduz, Cumhur, Cogulu, Ozgur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823505/
https://www.ncbi.nlm.nih.gov/pubmed/27110565
http://dx.doi.org/10.1155/2016/5312674
_version_ 1782425932209848320
author Erturk, Biray
Karaca, Emin
Aykut, Ayca
Durmaz, Burak
Guler, Ahmet
Buke, Baris
Yeniel, Ahmet Ozgur
Ergenoglu, Ahmet Mete
Ozkinay, Ferda
Ozeren, Mehmet
Kazandi, Mert
Akercan, Fuat
Sagol, Sermet
Gunduz, Cumhur
Cogulu, Ozgur
author_facet Erturk, Biray
Karaca, Emin
Aykut, Ayca
Durmaz, Burak
Guler, Ahmet
Buke, Baris
Yeniel, Ahmet Ozgur
Ergenoglu, Ahmet Mete
Ozkinay, Ferda
Ozeren, Mehmet
Kazandi, Mert
Akercan, Fuat
Sagol, Sermet
Gunduz, Cumhur
Cogulu, Ozgur
author_sort Erturk, Biray
collection PubMed
description Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies.
format Online
Article
Text
id pubmed-4823505
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48235052016-04-24 Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome Erturk, Biray Karaca, Emin Aykut, Ayca Durmaz, Burak Guler, Ahmet Buke, Baris Yeniel, Ahmet Ozgur Ergenoglu, Ahmet Mete Ozkinay, Ferda Ozeren, Mehmet Kazandi, Mert Akercan, Fuat Sagol, Sermet Gunduz, Cumhur Cogulu, Ozgur Biomed Res Int Research Article Background. Currently, the data available on the utility of miRNAs in noninvasive prenatal testing is insufficient in the literature. We evaluated the expression levels of 14 miRNAs located on chromosome 21 in maternal plasma and their utility in noninvasive prenatal testing of Down Syndrome. Method. A total of 56 patients underwent invasive prenatal testing; 23 cases were carrying Down Syndrome affected fetuses, and 33 control cases carrying unaffected, normal karyotype fetuses were included for comparison. Indications for invasive prenatal testing were advanced maternal age, increased risk of Down Syndrome in screening tests, and abnormal finding in the sonographic examination. In both the study and control groups, all the pregnant women were at 17th and 18th week of gestation. miRNA expression levels were measured using real-time RT-PCR. Results. Significantly increased maternal plasma levels of miR-3156 and miR-99a were found in the women carrying a fetus with Down Syndrome. Conclusion. Our results provide a basis for multicenter studies with larger sample groups and microRNA profiles, particularly with the microRNAs which were found to be variably expressed in our study. Through this clinical research, the utility of microRNAs in noninvasive prenatal testing can be better explored in future studies. Hindawi Publishing Corporation 2016 2016-03-24 /pmc/articles/PMC4823505/ /pubmed/27110565 http://dx.doi.org/10.1155/2016/5312674 Text en Copyright © 2016 Biray Erturk et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Erturk, Biray
Karaca, Emin
Aykut, Ayca
Durmaz, Burak
Guler, Ahmet
Buke, Baris
Yeniel, Ahmet Ozgur
Ergenoglu, Ahmet Mete
Ozkinay, Ferda
Ozeren, Mehmet
Kazandi, Mert
Akercan, Fuat
Sagol, Sermet
Gunduz, Cumhur
Cogulu, Ozgur
Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title_full Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title_fullStr Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title_full_unstemmed Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title_short Prenatal Evaluation of MicroRNA Expressions in Pregnancies with Down Syndrome
title_sort prenatal evaluation of microrna expressions in pregnancies with down syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823505/
https://www.ncbi.nlm.nih.gov/pubmed/27110565
http://dx.doi.org/10.1155/2016/5312674
work_keys_str_mv AT erturkbiray prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT karacaemin prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT aykutayca prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT durmazburak prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT gulerahmet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT bukebaris prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT yenielahmetozgur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT ergenogluahmetmete prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT ozkinayferda prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT ozerenmehmet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT kazandimert prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT akercanfuat prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT sagolsermet prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT gunduzcumhur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome
AT coguluozgur prenatalevaluationofmicrornaexpressionsinpregnancieswithdownsyndrome